A Japanese case of VEXAS syndrome after COVID-19 vaccination: Comparison with previously reported cases

5Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is a novel adult-onset autoinflammatory disorder caused by variants in the UBA1 gene. Here, we report a Japanese case of VEXAS syndrome in which symptoms began 1 day after the second booster dose of a coronavirus disease 2019 (COVID-19) messenger ribonucleic acid vaccine, and a UBA1 variant was subsequently confirmed. Combined with the three cases reported thus far, this suggests that the COVID-19 vaccine may be one of the triggers for development of VEXAS syndrome in Asian populations. Since COVID-19 vaccines have been reported to be associated with various autoinflammatory and autoimmune diseases, it is important to continue to pay close attention to the relationship between COVID-19 vaccines and VEXAS syndrome.

Cite

CITATION STYLE

APA

Miyagi, Y., Kobayashi, H., Umebayashi, Y., Okimura, A., Nakatsugawa, M., Maeda, A., … Aoki, A. (2025). A Japanese case of VEXAS syndrome after COVID-19 vaccination: Comparison with previously reported cases. Modern Rheumatology Case Reports, 9(1), 218–223. https://doi.org/10.1093/mrcr/rxae054

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free